Abstract: Disclosed herein are methods of enhancing the stability of a sustained pharmaceutical composition comprising an active agent and a polymer and methods of preparing such pharmaceutical compositions with enhanced stability.

Abstract: Disclosed herein are methods of enhancing the stability of a sustained pharmaceutical composition comprising an active agent and a polymer and methods of preparing such pharmaceutical compositions with enhanced stability.

Abstract: Disclosed herein are methods of enhancing the stability of a sustained pharmaceutical composition comprising an active agent and a polymer and methods of preparing such pharmaceutical compositions with enhanced stability.

Abstract: Hydroxyterminated PHA is produced by cultivating a PHA-producing microorganism in the presence of an aliphatic diol or an aliphatic polyol. High molecular weight hydroxy-terminated PHA is obtainable by the disclosed process, and is useful in the production of graft, block and random polymers and copolymers with other monomers, oligomers and polymers containing appropriate functionality and end group compatibility. The hydroxyterminated PHAs of the invention display improved thermal stability compared with PHAs not modified to contain increased end-group hydroxyl content. In addition, a branched PHA structure is provided by melt processing polyol terminated PHA.

Abstract: Methods for the biosynthesis of polyhydroxyalkanoate homopolymers and copolymers are described. In a preferred embodiment, the polymers have a single mode molecular weight distribution, and more preferably have a distribution of between about 2 and about 4, and most preferably about 2.1 or 2.5.

Abstract: Hydroxyterminated PHA is produced by cultivating a PHA-producing microorganism in the presence of an aliphatic diol or an aliphatic polyol. High molecular weight hydroxy-terminated PHA is obtainable by the disclosed process, and is useful in the production of graft, block and random polymers and copolymers with other monomers, oligomers and polymers containing appropriate functionality and end group compatibility.

Abstract: Hydroxyterminated PHA is produced by cultivating a PHA-producing microorganism in the presence of an aliphatic diol or an aliphatic polyol. High molecular weight hydroxy-terminated PHA is obtainable by the disclosed process, and is useful in the production of graft, block and random polymers and copolymers with other monomers, oligomers and polymers containing appropriate functionality and end group compatibility. The hydroxyterminated PHAs of the invention display improved thermal stability compared with PHAs not modified to contain increased end-group hydroxyl content. In addition, a branched PHA structure is provided by melt processing polyol terminated PHA.

Abstract: Methods for the biosynthesis of polyhydroxyalkanoate homopolymers and copolymers are described. In a preferred embodiment, the polymers have a single mode molecular weight distribution, and more preferably have a distribution of between about 2 and about 4, and most preferably about 2.1 or 2.5.

Abstract: Hydroxyterminated PHA is produced by cultivating a PHA-producing microorganism in the presence of an aliphatic diol or an aliphatic polyol. High molecular weight hydroxy-terminated PHA is obtainable by the disclosed process, and is useful in the production of graft, block and random polymers and copolymers with other monomers, oligomers and polymers containing appropriate functionality and end group compatibility.

Abstract: A method is disclosed for significantly diminishing the rate of degradation of naturally-produced .gamma.-PGA in a .gamma.-PGA-producing cell culture. Also, a method is disclosed for significantly decreasing the water solubility coefficient of naturally-produced .gamma.-PGA by forming derivatives of .gamma.-PGA. In addition, a polymer solution is disclosed which includes a polysaccharide component and a .gamma.-PGA component.